Revvity, Inc.
RVTYHealthcareNASDAQDiagnostics & Research · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Revvity, Inc. focuses on Diagnostics & Research services and products. Revvity, Inc. provides health sciences solutions, technologies, and services. The $14.53B market capitalization puts RVTY squarely in large-cap range for its industry. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Market Cap
$14.53B
Beta
1.09
P/E (TTM)
62.61
P/E (Fwd)
22.10
EPS (TTM)
$2.08
EPS (Fwd)
$5.89
ROE
3.2%
ROA
2.4%
Cash
$1.02B
Total Debt
$3.34B
Free CF
$605.0M
52W Change
53.1%
Annual Financials
Cash vs Debt
Where RVTY stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RVTY finished 28.76% above its 150-day moving average ($101.69) and 28.54% above its 200-day moving average ($101.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RVTY overbought or oversold?
At the September 3, 2026 close, RVTY's RSI(14) was 71.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, RVTY has $1.02B in cash with $3.34B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $605.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 3.2%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.4% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.31B to $2.86B.
At over 50x earnings, RVTY carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing RVTY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.